Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Clin Lymphoma Myeloma Leuk. 2011 Jun;11(3):257-60. doi: 10.1016/j.clml.2011.03.012. Epub 2011 Apr 20.
Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials.
We reviewed the Surveillance, Epidemiology, and End Results (SEER) registry and compared survival trends among DLBCL patients from 1973 to 2004.
We identified 59,728 patients (mean age, 63 years; 54.4% men, 86.7% white) and had staging information for 57%, including 30% early-stage (I/II) and 27% advanced-stage (III/IV). Median overall survival (OS) from 1973 to 1979, 1980 to 1989,1990 to 1999, and 2000 to 2004 was 15, 18, 20, and 47 months, respectively (P < .005). For the period from 2000 to 2004, 4-year OS was 46%. Outcome was better in white patients than in black (47 months versus 29 months) (P = .001). Median OS for patients younger than 60 years old was not reached versus 23 months for patients older than 60 years.
The outcome of DLBCL in the United States has improved significantly in the era of monoclonal antibodies; however, racial disparities remain.
在美国，弥漫性大 B 细胞非霍奇金淋巴瘤（DLBCL）的结果并未在临床试验之外的情况下报告。
我们回顾了监测、流行病学和最终结果（SEER）登记处，并比较了 1973 年至 2004 年期间 DLBCL 患者的生存趋势。
我们确定了 59728 名患者（平均年龄 63 岁；54.4%为男性，86.7%为白人），其中 57%有分期信息，包括 30%的早期（I/II 期）和 27%的晚期（III/IV 期）。1973 年至 1979 年、1980 年至 1989 年、1990 年至 1999 年和 2000 年至 2004 年的中位总生存期（OS）分别为 15、18、20 和 47 个月（P<.005）。对于 2000 年至 2004 年期间，4 年 OS 为 46%。白人患者的预后优于黑人患者（47 个月对 29 个月）（P=.001）。年龄小于 60 岁的患者中位 OS 未达到，而年龄大于 60 岁的患者中位 OS 为 23 个月。
在单克隆抗体时代，美国 DLBCL 的结果有了显著改善；然而，种族差异仍然存在。
